tolerize

tol·er·ize

(tol'ĕr-īz),
To induce tolerance.
References in periodicals archive ?
Farthing et al., "Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo," Stem Cells, vol.
Under SQZ's tolerance programme, including its new T1D programme, auto-antigens are delivered to cells in a way that leverages naturally occurring biological processes to tolerize the patient's immune system and potentially eliminate its ability to attack healthy tissue.
Therefore, modulation of T-cell function with, for example, soluble T-cell peptides to tolerize T-cells and/or enhance Tregs to downregulate the anti-PLA2R/THSD7A response is promising a new treatment strategy for iMN [28].
Second, with amazing insight, the Creator allows fetal stem cells to cross into the mother's body to tolerize her immune system, to make the mother's immune system receptive to the foreign tissue of the fetus.
DC-STAMP lentiviral vector-OVA in mice tolerize OT-I CD8+ and OT-II CD4+ T-cell responses, leading to elimination and functional inactivation of CD4 and CD8 T cells in peripheral organs and in the thymus [201].
The method could be applied to hESC transplantation by using hematopoietic cells derived from a particular hESC line to "tolerize" a patient to any other transplanted tissue derived from the same hESC line.
Recruitment is continuing for the second phase of the DPT-1, which is investigating whether oral insulin can "tolerize" and prevent type 1 diabetes in first- and second-degree relatives at lower (25%-50%) risk for developing the disease within 5 years.
Recruitment is continuing for the second phase of the DPT-i study, which is investigating whether oral insulin can "tolerize" and prevent type 1 diabetes in first and second-degree relatives who are at lower (25%-50%) risk for developing the disease within 5 years.
Recruitment is continuing for the second phase of the DPT-1, which is investigating whether oral insulin can "tolerize" and prevent type I diabetes in first- and second-degree relatives at lower (25%-50%) risk for developing the disease within 5 years.
Based on a mouse model it has been shown that HLAG-positive tumor cells develop and tolerize the host antitumor immune response in vivo [108].
Recently, the development of animal models established the proof of concept that an HLA-[G.sup.+] tumor cell can develop and tolerize the host antitumor immune response in vivo [30, 31].
Over the years, a number of rodent studies have demonstrated that there is a hierarchy of susceptibility between different graft types and sizes with skin and intestine being the most prone to rejection while islets, hearts, kidneys, and livers are progressively more easy to tolerize [46-49].